Bluejay Diagnostics sets sights on H1 2027 FDA submission for Symphony IL-6 test

Seeking Alpha · November 13, 2026, 15:18 UTC

Tickers: $BJDX

Topics: FDA approval process medical diagnostics product development

Read the full article at Seeking Alpha

Part of the story PAVmed Reports Q3 2026 Revenue Growth and Lucid Diagnostics Medicare Reimbursement Milestone (2 articles)

More World news

Blue Moon Metals Inc. Reports Q3 GAAP EPS of -$0.24 Seeking Alpha · November 13, 2026, 18:55 UTC
Scorpio Gold Corporation Reports GAAP EPS of -$0.01 Seeking Alpha · November 13, 2026, 18:57 UTC
Goldman Sachs Targets Underwriting Fees and Wealth Management Growth via Anthropic IPO CNBC · November 13, 2026, 18:44 UTC
SEC Proposes Amendments to Executive Compensation Disclosure Rules Seeking Alpha · November 13, 2026, 18:53 UTC
Highlander Silver Reports Q3 Revenue of $37.75 Million and GAAP EPS of -$0.08 Seeking Alpha · November 13, 2026, 18:49 UTC
DiaMedica Therapeutics Reports Clinical Milestones and Long-Term Cash Runway Through 2027 Seeking Alpha · November 13, 2026, 18:50 UTC
CFRA Upgrades Delta Air Lines to Buy Rating Seeking Alpha · November 13, 2026, 18:50 UTC
City National Bank Appoints Jeffrey LaBauve as Head of Commercial Real Estate Banking PR Newswire · November 13, 2026, 18:50 UTC
Commerce Secretary Howard Lutnick Faces Scrutiny Over Cantor Fitzgerald’s Nvidia Holdings and National Security Concerns CNBC · November 13, 2026, 18:32 UTC
Azitra Reports Q3 GAAP EPS of -$0.29, Missing Estimates by $0.04 Seeking Alpha · November 13, 2026, 18:39 UTC